IMVT vs ROIV
IMVT: Immunovant is a clinical-stage immunology company developing IMVT-1402, a potentially best-in-class FcRn inhibitor to treat autoimmune diseases driven by pathogenic IgG antibodies. ROIV: Roivant Sciences is a biopharma-tech incubator that uses a 'Vant' subsidiary model and computational discovery tools to accelerate the development of transformative therapies for autoimmune and inflammatory diseases.
Side-by-side fundamentals
| Metric | IMVT | ROIV | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $39.05 | $34.91 | |
| Market cap as of 2026-07-23 | $8.0B | $25.1B | |
| PEG as of 2026-07-23 | -11.69 | -0.68 | IMVT lower |
| Net margin as of 2026-07-23 | n/a | -3629.2% | |
| Gross margin as of 2026-07-23 | n/a | +84.4% | |
| Operating margin as of 2026-07-23 | n/a | -6102.2% | |
| ROE as of 2026-07-23 | -68.2% | -6.9% | ROIV higher |
| ROA as of 2026-07-23 | -62.2% | -5.7% | ROIV higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -89.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -36.0% | |
| Beta as of 2026-07-23 | 0.81 | 1.12 | |
| 1-year return as of 2026-07-22 close | +123.3% | +203.6% | ROIV higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.